DNA biomarkers in urine are important diagnostic and prognostic indicators for bladder cancer. Many genetic alterations have been identified in the urinary DNA. However, not all bladder tumors harbor mutations in the most commonly altered oncogenes. Thus, to reach satisfactory sensitivity and specificity a new diagnostic test should include multiple biomarkers. The investigators will conduct a prospective evaluation of a panel of mutations in urine-DNA test for the detection of urothelial bladder carcinoma in patients with gross hematuria for cystoscope.
Urinary DNA representative of the tumour genome provide a promising resource as a liquid biopsy for non-invasive genomic profiling of urothelial bladder cancers. Voided urine samples will be collected prior to cystoscopy. Cell free DNA and cellular DNA will both be extracted and analyzed. A blood sample will be taken. In patients with bladder wall findings suspicious of cancer, a bladder wall biopsy will be taken and submitted for histopathology examination, according to clinical standard practice. Next generation sequencing will be applied and hotspots mutations in DNA from urine, blood and tumor. Logistic regression was used to analyze the association between predictor variables and bladder cancer. The investigators will confirm a couple of common mutations occured in urine-DNA and blood-derived DNA simultaneously and verify the specificity and sensitivity of individual variance or mutation combinations to establish an predictive model with optimal robustness in diagnosis of bladder cancer. Moreover, external consistency test will be performed on subsequent patients collection.
Study Type
OBSERVATIONAL
Enrollment
125
The obtained DNA from the urine, blood and tumor (optional) will be tested by next generation sequencing for each arm.
Xiangya Hospital of Central South Univeristy
Changsha, Hunan, China
sensitivity of urinalysis by Urine-DNA test
number of patients "declared positive" with the Urine-DNA test among the patients actually suffering from bladder carcinoma
Time frame: through study completion, an average of 8 months
specificity of urinalysis by Urine-DNA test
number of patients "declared negative" with the Urine-DNA test among the patients without bladder carcinoma
Time frame: through study completion, an average of 8 months
Identification of positive urine-DNA test results with the next generation sequencing
Identification of presence of positive urine-DNA test results with the designed panel.
Time frame: through study completion, an average of 8 months
Identification of urine-DNA mutations with the next generation sequencing to create an diagnosis algorithm.
Identification of presence or absence of the mutations in urine-DNA with the next generation sequencing to create an idiagnosis algorithm
Time frame: through study completion, an average of 8 months
sensitivity of blood DNA test
number of patients "declared positive" with the blood-DNA test among the patients actually suffering from bladder carcinoma
Time frame: through study completion, an average of 8 months
specificity of blood DNA test
number of patients "declared negative" with the blood DNA test among the patients without bladder carcinoma
Time frame: through study completion, an average of 8 months
comparison of the sensitivity of the urine DNA versus blood DNA test
number of patients "declared positive" with the urine DNA test versus patients "declared positive" with the blood DNA test.
Time frame: through study completion, an average of 8 months
comparison of the specificity of the urine DNA versus blood DNA test
number of patients "declared negative" with the urine DNA test versus patients "declared negative" with the blood DNA test.
Time frame: through study completion, an average of 8 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.